The Human Variable 

The true U.S. burden of Lyme disease is estimated at 5 - 7 million Americans, according to CYNAERA’s US-CCUC™ 2026 prevalence model, substantially higher than the roughly 400,000 to 500,000 diagnoses recorded annually. By accounting for underdiagnosis, chronic illness, and fragmented surveillance, this paper reframes Lyme disease as a major chronic illness burden rather than a narrowly counted regional infection.

P.R.O.O.F. GPT™ was developed to support harm-aware analysis in complex systems. P.R.O.O.F. stands for People Revealing Overlooked & Outdated Failures. The system applies the Moral Adinig Method to identify omissions, delays, representation gaps, and outdated assumptions that increase risk exposure. Its purpose is not to assign blame or rank vulnerability, but to improve system reliability and safeguard design.

The Moral Adinig Method™ is a harm-aware AI training framework that embeds contextual reasoning, moral memory, and relational identity scaffolding to improve safety and reliability. Cross-model evaluations show reduced harmful recommendations, stronger bias translation into protective guidance, and improved decision integrity in complex, high-risk environments without modifying model weights. If you want an alternate tone that leans slightly more policy-facing:

The Aligned Intelligence Method (AIM™) is a human-readable, machine-interpretable knowledge framework that embeds interpretive guardrails directly into source documents. AIM aligns lived patterns, longitudinal data, domain reasoning, and environmental context into unified analytic references that support both human understanding and consistent AI interpretation.

The Diagnostic Acceleration Blueprint™ modernizes IACC diagnostics by combining reuse-first biospecimen pipelines, digital consent, and ML-driven multi-system fingerprints. This framework cuts timelines by 95%, costs by 99%, and eliminates multi-year delays rooted in outdated systems.

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti